Get the Stockscreener App
16.52
3.11%
-0.53
After Hours:
16.52
Viridian Therapeutics Inc stock is traded at $16.52, with a volume of 498.49K.
It is down -3.11% in the last 24 hours and up +10.13% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$17.05
Open:
$17.29
24h Volume:
498.49K
Relative Volume:
0.64
Market Cap:
$1.35B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-3.8871
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
-3.05%
1M Performance:
+10.13%
6M Performance:
-8.88%
1Y Performance:
+14.17%
1-Day Range:
$16.46
$17.33
1-Week Range:
$15.96
$17.48
52-Week Range:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
16.52 | 1.39B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
What drives Viridian Therapeutics Inc. stock priceTremendous gains - Jammu Links News
(VRDN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
What analysts say about Viridian Therapeutics Inc. stockExtraordinary performance - Jammu Links News
Principal Financial Group Inc. Acquires 30,392 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
Why Viridian Therapeutics Inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
What makes Viridian Therapeutics Inc. stock price move sharplyFast Moving Stock Alerts - Newser
How Viridian Therapeutics Inc. stock performs during market volatilitySafety First Trading Signals - Newser
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $38 - 富途牛牛
Amalgamated Bank Has $34,000 Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Evercore ISI Lowers Viridian Therapeutics Price Target to $38 - AInvest
Viridian Therapeutics Sees Relative Strength Rating Improve To 79 - MSN
(VRDN) Investment Analysis - news.stocktradersdaily.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Viridian Therapeutics: Fueling R&D Breakthroughs Through Strategic Equity Incentives - AInvest
Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment? - simplywall.st
(VRDN) On The My Stocks Page - news.stocktradersdaily.com
When (VRDN) Moves Investors should Listen - news.stocktradersdaily.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.56 Average Target Price from Analysts - Defense World
Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal year - Investing.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by California State Teachers Retirement System - Defense World
Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha
Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats By Investing.com - Investing.com Nigeria
Ameriprise Financial Inc. Increases Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics to Participate in Upcoming June 2025 Investor Conferences - BioSpace
Viridian Therapeutics to Participate in Upcoming June Investor C - GuruFocus
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire
Bank of America Corp DE Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 13,990 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLC - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Millennium Management LLC - Defense World
Viridian reports long-term durability data, secures FDA designation for TED therapy - Eyes On Eyecare
Needham & Company LLC Reiterates “Buy” Rating for Viridian Therapeutics (NASDAQ:VRDN) - Defense World
Viridian Therapeutics’ veligrotug shows durability in Phase III TED trial - Yahoo Finance
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $36.70 Average Target Price from Analysts - Defense World
Veligrotug Shows Durability for Thyroid Eye Disease in Phase 3 Trial Results - HCPLive
Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalysts - Investing.com Nigeria
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):